One of the pathways of interest for targeting in the treatment of MM has been the phosphoinositide‐3‐kinase (PI3K)/Akt signaling cascade, the activation of which is induced by interactions between MM cells and bone marrow stromal cells within the bone marrow microenvironment [12, 13]. This evidence concerns the gene AKT1 and Miyoshi myopathy.